Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 911-238-8 | CAS number: -
Toxicological Summary
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- exposure based waiving
Acute/short term exposure
- Hazard assessment conclusion:
- exposure based waiving
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- exposure based waiving
Acute/short term exposure
- Hazard assessment conclusion:
- hazard unknown but no further hazard information necessary as no exposure expected
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 3.2 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 100
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 40 mg/kg bw/day
- Most sensitive endpoint:
- acute toxicity
DNEL related information
- Overall assessment factor (AF):
- 50
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- skin irritation/corrosion
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- skin irritation/corrosion
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - workers
The basic dose descriptor for dermal short-term (acute) exposure was taken from an acute dermal toxicity study with rats and an LD50 >2000 mg per kg body weight.
Basic dose descriptor for long-term exposure: In a 90-day oral repeated dose toxicity study (gavage) with Resin 835 A in the rat the NOAEL was 316 mg per kg body weight for males and females. In a Prenatal Developmental Toxicity Study the No Observed Adverse Effect Level (NOAEL) for maternal toxicity and fetal developmental toxicity was 250 mg/kg/day. Due to the longer exposure period the NOAEL of 316 mg per kg body weight determined in the sub-chronic study was taken as the basic dose descriptor. This is not conflicting with the lower NOAEL in the Prental Developmental Toxicity Study because there is no evidence for a higher sensitivity in this study.
No DNELs are derived for acute or long-term exposure via inhalation, as exposure via inhalation is not likely: No dust particles are generated and the vapour pressure Is very low (in the range of 10E-4 to 10E-5 Pa at 25 °C).
All references are made to the"Guidance on information requirements and chemical safety assessment, Chapter R.8: Characterisation of dose [concentration]-response for human health"
The assessment factors (AF) used are given in the following order:
Interspecies metabolic rate for the conversion of the results from rat to human: 4 (dermal, oral)
- Interspecies remaining differences: 2.5
- Intraspecies: 5
-
Factor to cover the ratio LD50/NOEL: 1
or to extrapolate from sub-chronic to chronic exposure: 2
- Dose response reliability: 1
- Quality of whole database: 1
as inRefTable R.8-6.
Acute – short-term exposure, systemic effects:
Dermal
Dose descriptor starting point:
LD50dermal,acute >2000 mg/kg bw.
Overall AF= 4*2.5*5*1*1*1 = 50.
As no toxic signs were noted at the LD50,dermal the LD50,dermal is considered to be also the NOAEL,dermal. A factor of 1 is therefore applied to cover the ratio LD50/NOAEL.
Long-term exposure, systemic effects:
Dermal
Dose descriptor starting point:
NOAELdermal = NOAELoral,90d = 316 mg/kg bw.
The dermal absorption is considered to be generally lower as the oral absorption. As a worst case it is therefore assumed that the NOAELdermal = NOAELoral.
Overall AF= 4*2.5*5*2*1*1 = 100.
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- exposure based waiving
Acute/short term exposure
- Hazard assessment conclusion:
- exposure based waiving
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- exposure based waiving
Acute/short term exposure
- Hazard assessment conclusion:
- exposure based waiving
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.53 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 600
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 20 mg/kg bw/day
- Most sensitive endpoint:
- acute toxicity
DNEL related information
- Overall assessment factor (AF):
- 100
Local effects
Long term exposure
- Hazard assessment conclusion:
- no-threshold effect and/or no dose-response information available
- Most sensitive endpoint:
- skin irritation/corrosion
Acute/short term exposure
- Hazard assessment conclusion:
- no-threshold effect and/or no dose-response information available
- Most sensitive endpoint:
- skin irritation/corrosion
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.53 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 600
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 20 mg/kg bw/day
- Most sensitive endpoint:
- acute toxicity
DNEL related information
- Overall assessment factor (AF):
- 100
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - General Population
The basic dose descriptor for dermal short-term (acute) exposure was taken from an acute dermal toxicity study with rats and an LD50 >2000 mg per kg body weight.
The basic dose descriptor for oral short-term (acute)exposure was taken from an acute oral toxicity study with rats and an LD50 >2000 mg per kg body weight.
Basic dose descriptor for long-term exposure: In a 90-day oral repeated dose toxicity study (gavage) with Resin 835 A in the rat the NOAEL was 316 mg per kg body weight for males and females. In a Prenatal Developmental Toxicity Study the No Observed Adverse Effect Level (NOAEL) for maternal toxicity and fetal developmental toxicity was 250 mg/kg/day. Due to the longer exposure period the NOAEL of 316 mg per kg body weight determined in the sub-chronic study was taken as the basic dose descriptor. This is not conflicting with the lower NOAEL in the Prental Developmental Toxicity Study because there is no evidence for a higher sensitivity in this study.
No DNELs are derived for acute or long-term exposure via inhalation, as exposure via inhalation is not likely: No dust particles are generated and the vapour pressure Is very low (in the range of 10E-4 to 10E-5 Pa at 25 °C).
All references are made to the"Guidance on information requirements and chemical safety assessment, Chapter R.8: Characterisation of dose [concentration]-response for human health"
The assessment factors (AF) used are given in the following order:
Interspecies metabolic rate for the conversion of the results from rat to human: 4 (dermal, oral) or 1 (for inhalation)
- Interspecies remaining differences: 2.5
- Intraspecies: 10
- Factor to cover the ratio LD50/NOEL: 1 or to extrapolate from the sub-acute to chronic exposure: 6
- Dose response reliability: 1
- Quality of whole database: 1
as inRefTable R.8-6.
Acute – short-term exposure, systemic effects:
Dermal
Dose descriptor starting point:
LD50dermal,acute >2000 mg/kg bw.
Overall AF = 4*2.5*10*1*1*1 = 100.
As no toxic signs were noted at the LD50,dermal the LD50,dermal is considered to be also the NOAEL,dermal. A factor of 1 is therefore applied to cover the ratio LD50/NOAEL.
Oral
Dose descriptor starting point:
LD50oral,acute >2000 mg/kg bw.
Overall AF = 4*2.5*10*1*1*1 = 100.
As no toxic signs were noted at the LD50,oral the LD50,oral is considered to be also the NOAEL,oral. A factor of 1 is therefore applied to cover the ratio LD50/NOAEL.
Long-term exposure, systemic effects:
Dermal
Dose descriptor starting point:
NOAELdermal = NOAELoral,90d = 316 mg/kg bw.
The dermal absorption is considered to be generally lower as the oral absorption. As a worst case it is therefore assumed that the NOAELdermal = NOAELoral.
Overall AF = 4*2.5*10*6*1*1 = 600.
Oral
NOAELoral = NOAELoral,90d = 316 mg/kg bw.
Overall AF = 4*2.5*10*6*1*1 = 600.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
